Rocket Pharmaceuticals (RCKT) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts RCKT Hot Sheet
Join SI Premium – FREE
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.38), $0.05 better than the analyst estimate of ($0.43).
For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herc Holdings (HRI) Tops Q3 EPS by 95c ; Offers Guidance
- CenterPoint Energy (CNP) Tops Q3 EPS by 4c; offers guidance
- Smithfield Foods, Inc. (SFD) Reports Q3 EPS of $0.26
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
